Cellular Senescence in the Pathogenesis of Benign Prostatic Hyperplasia
良性前列腺增生发病机制中的细胞衰老
基本信息
- 批准号:8046455
- 负责人:
- 金额:$ 22.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-03-24 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AgeAgingAnatomyBenign Prostatic HypertrophyBiologicalBiological ModelsCell AgingCell CycleCellsDevelopmentDiseaseEpithelialEpithelial CellsEvaluationFGF2 geneFGF7 geneFunctional disorderGalactosidaseGoalsGrowthGrowth FactorHealthHepatocyte Growth FactorHumanHyperplasiaIL8 geneIn VitroInsulin-Like Growth Factor IIInterleukin-1LeadLifeLightMedicalModelingMorbidity - disease rateOperative Surgical ProceduresPathogenesisPathologyPeripheralPreventiveProcessProstateProstaticProstatic EpitheliumProstatic TissueProtein IsoformsProteinsPublishingResearchRoleSecondary toSeveritiesStem Cell FactorStromal CellsTestingTimeTissuesTransgenic MiceTransgenic ModelUrinary tractage relatedautocrinebasecytokinehuman diseasehuman tissuein vivomenmouse modelolder menoxidative DNA damageparacrinesenescencetelomere
项目摘要
DESCRIPTION (provided by applicant): Cellular senescence limits the proliferation of human cells and can be induced by a variety of cellular alterations, both intrinsic and extrinsic. Senescent cells accumulate in human tissues, including the prostate, with increasing age. These senescent cells have altered function, including increased expression of proinflammatory cytokines that can alter the function of adjacent cells. Benign prostatic hyperplasia (BPH) is the single most common pathology of aging men. Based on our published studies we hypothesize that senescence of a subset of epithelial cells in BPH tissue leads to release of cytokines and growth factors that, through direct and indirect actions, drives increased proliferation of adjacent non-senescent epithelial cells and stromal cells and ultimately prostatic tissue growth in aging men. We propose to characterize the mechanisms by which cellular senescence can promote the development of benign prostatic hyperplasia. Two Specific Aims are proposed. In Specific Aim 1, we will examine the underlying cellular alterations leading to prostatic epithelial senescence in vitro and in vivo; determine the types of cytokines and growth factors expressed by senescent epithelial cells in vitro; evaluate whether these same proteins are expressed at increased levels in BPH tissue in vivo and quantitatively evaluate the extent to which there is coexpression of these cytokines and growth factors at the cellular level in vivo with markers of senescence, including key cell cycle regulator proteins such as p21 and p16. In Specific Aim 2 we will use primary cultures of prostatic epithelial and stromal cells, the reactive stroma model system and transgenic models to examine the biological activities of the identified cytokines/growth factors and model potential autocrine and paracrine activities of those factors that are increased in BPH in vivo. In addition, we will establish a transgenic mouse model of epithelial senescence and examine the biological impact of epithelial senescence in this mouse model. Benign prostatic hyperplasia causes considerable morbidity in older men, with up to 30% of men requiring treatment for this condition, and with more than one billion dollars spent on the medical and surgical treatment of this disease annually. These studies will make a fundamental contribution to our understanding of the role of cellular senescence in the pathogenesis of this common disease and lead to more effective preventive treatments and medical therapies. PUBLIC HEALTH RELEVANCE: Benign prostatic hyperplasia causes considerable morbidity in older men by blocking the urinary tract and up to 30% of men will require treatment for this condition at some time in their lives, with more than one billion dollars spent on the medical and surgical treatment of this disease annually. We believe these studies will make a fundamental contribution to our understanding the causes of this common disease and by doing so lead to more effective preventive treatments and medical therapies.
描述(由申请人提供):细胞衰老限制了人类细胞的增殖,并且可以通过多种细胞内在和外在的改变来诱导。随着年龄的增长,衰老细胞在包括前列腺在内的人体组织中积累。这些衰老细胞的功能发生了改变,包括促炎细胞因子的表达增加,从而改变了邻近细胞的功能。良性前列腺增生(BPH)是老年男性最常见的病症。根据我们发表的研究,我们假设 BPH 组织中一部分上皮细胞的衰老导致细胞因子和生长因子的释放,通过直接和间接的作用,驱动邻近非衰老上皮细胞和基质细胞的增殖增加,并最终促进前列腺增生。老年男性的组织生长。我们建议描述细胞衰老促进良性前列腺增生发展的机制。提出了两个具体目标。在具体目标 1 中,我们将在体外和体内检查导致前列腺上皮衰老的潜在细胞改变;体外确定衰老上皮细胞表达的细胞因子和生长因子的类型;评估这些相同的蛋白质在体内 BPH 组织中的表达水平是否增加,并定量评估这些细胞因子和生长因子在体内细胞水平上与衰老标志物共表达的程度,包括关键的细胞周期调节蛋白,例如第 21 页和第 16 页。在具体目标 2 中,我们将使用前列腺上皮细胞和基质细胞的原代培养物、反应性基质模型系统和转基因模型来检查已识别的细胞因子/生长因子的生物活性,并模拟这些因子的潜在自分泌和旁分泌活性。体内良性前列腺增生。此外,我们将建立上皮衰老的转基因小鼠模型,并研究上皮衰老在该小鼠模型中的生物学影响。良性前列腺增生在老年男性中造成相当大的发病率,高达 30% 的男性需要治疗这种疾病,每年用于该疾病的内科和手术治疗的费用超过 10 亿美元。这些研究将为我们理解细胞衰老在这种常见疾病发病机制中的作用做出根本性贡献,并带来更有效的预防性治疗和药物治疗。公共健康相关性:良性前列腺增生会阻塞尿路,导致老年男性发病率相当高,多达 30% 的男性在一生中的某个时候需要治疗这种疾病,医疗和手术费用超过 10 亿美元每年治疗一次这种疾病。我们相信这些研究将为我们了解这种常见疾病的原因做出根本性贡献,并由此带来更有效的预防性治疗和药物治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael M Ittmann其他文献
Michael M Ittmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael M Ittmann', 18)}}的其他基金
Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer
TMPRSS2/ERG 融合基因在前列腺癌中的高度特异性靶向
- 批准号:
8732393 - 财政年份:2014
- 资助金额:
$ 22.91万 - 项目类别:
Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer
TMPRSS2/ERG 融合基因在前列腺癌中的高度特异性靶向
- 批准号:
9487872 - 财政年份:2014
- 资助金额:
$ 22.91万 - 项目类别:
A novel oncogenic axis in African American prostate cancer
非裔美国人前列腺癌的新致癌轴
- 批准号:
10158403 - 财政年份:2014
- 资助金额:
$ 22.91万 - 项目类别:
A novel oncogenic axis in African American prostate cancer
非裔美国人前列腺癌的新致癌轴
- 批准号:
10455444 - 财政年份:2014
- 资助金额:
$ 22.91万 - 项目类别:
Mechanisms of Cytokine Induced Lower Urinary Track Pathology
细胞因子诱导下尿路病理学机制
- 批准号:
8566162 - 财政年份:2012
- 资助金额:
$ 22.91万 - 项目类别:
Mechanisms of Cytokine Induced Lower Urinary Track Pathology
细胞因子诱导下尿路病理学机制
- 批准号:
8445575 - 财政年份:2012
- 资助金额:
$ 22.91万 - 项目类别:
Mechanisms of Cytokine Induced Lower Urinary Track Pathology
细胞因子诱导下尿路病理学机制
- 批准号:
8549230 - 财政年份:2012
- 资助金额:
$ 22.91万 - 项目类别:
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
FGFR1 信号在不同细胞谱系中在前列腺癌进展中的作用
- 批准号:
8137691 - 财政年份:2009
- 资助金额:
$ 22.91万 - 项目类别:
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
FGFR1 信号在不同细胞谱系中在前列腺癌进展中的作用
- 批准号:
8334481 - 财政年份:2009
- 资助金额:
$ 22.91万 - 项目类别:
相似国自然基金
ALA光动力上调炎症性成纤维细胞ZFP36抑制GADD45B/MAPK通路介导光老化皮肤组织微环境重塑的作用及机制研究
- 批准号:82303993
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
YAP1-TEAD通过转录调控同源重组修复介导皮肤光老化的作用机制
- 批准号:82371567
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
下丘脑乳头上核-海马齿状回神经环路在运动延缓认知老化中的作用及机制研究
- 批准号:82302868
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
微纳核壳结构填充体系构建及其对聚乳酸阻燃、抗老化、降解和循环的作用机制
- 批准号:52373051
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
KIAA1429介导MFAP4-m6A甲基化修饰在紫外线诱导皮肤光老化中的作用和机制研究
- 批准号:82373461
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 22.91万 - 项目类别:
GPR39 as a Therapeutic Target in Aging-Related Vascular Cognitive Impairment and Dementia
GPR39 作为衰老相关血管认知障碍和痴呆的治疗靶点
- 批准号:
10734713 - 财政年份:2023
- 资助金额:
$ 22.91万 - 项目类别:
Functional analysis of an LGN-based visual prosthesis
基于 LGN 的视觉假体的功能分析
- 批准号:
10582766 - 财政年份:2023
- 资助金额:
$ 22.91万 - 项目类别:
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease
保留大脑 NAD 作为阿尔茨海默病的一种新型非淀粉样蛋白治疗策略
- 批准号:
10588414 - 财政年份:2023
- 资助金额:
$ 22.91万 - 项目类别:
High resolution lineage tracing of developmental hematopoiesis
发育造血的高分辨率谱系追踪
- 批准号:
10585400 - 财政年份:2023
- 资助金额:
$ 22.91万 - 项目类别: